Cdk4
Cdk4
Overview
Cyclin-dependent kinase 4 (CDK4) is a serine/threonine protein kinase that plays a central role in regulating cell cycle progression, specifically the transition from the G1 phase to the S phase. CDK4 exerts its activity by forming heterodimeric complexes with its regulatory partners, the D-type cyclins (cyclin D1, D2, and D3), which are required for kinase activation. Upon complex formation, CDK4 phosphorylates the retinoblastoma protein (Rb), releasing the transcription factor E2F and enabling transcription of genes necessary for S-phase entry and DNA replication. This mechanism positions CDK4 as a critical gatekeeper of proliferative signaling in normal development and a frequent target of dysregulation in human malignancies. CDK4 is closely related to and functionally redundant with CDK6 in many cellular contexts, and the two are commonly referred to jointly as CDK4/6.
Given its pivotal role in driving cell division, CDK4 has emerged as a major therapeutic target in oncology. Aberrant CDK4 activity — through gene amplification, cyclin D overexpression, or loss of endogenous inhibitors such as p16/CDKN2A — is implicated in a broad range of cancers. Small-molecule inhibitors selectively targeting CDK4/6 have been developed and approved clinically, most prominently for hormone receptor-positive (HR+), HER2-negative (HER2−) breast cancer, where these agents have transformed the treatment landscape in combination with endocrine therapy.
Focus of Latest Publications
Recent publications on Cdk4 have focused largely on its role as a therapeutic target in breast cancer and on the broader biological effects of CDK4/6 inhibition in the tumor microenvironment. One study reported that selective CDK4/6 inhibitors shifted tumor-associated macrophages from an M2-like to an M1-like phenotype, increased macrophage phagocytic capacity, and enhanced effector T cell-mediated immune responses. In that work, CDK4/6 inhibition also reduced p53 levels by altering p53 mRNA expression and promoting p53 protein degradation, and the combination of CDK4/6 inhibition with CD47 blockade suppressed breast cancer growth in preclinical models.
Several recent papers have also explored direct CDK4-targeted drug discovery. A synthesis study described novel triazolopyrimidine derivatives as selective CDK4 inhibitors, with molecular docking supporting binding to the CDK4 active site. In breast cancer cell lines, the most active compound showed low micromolar antiproliferative activity, limited toxicity toward normal fibroblasts, and induced G0/G1 cell-cycle arrest and apoptosis, consistent with a CDK4-dependent mechanism. Another publication developed a near-infrared-II fluorescent probe based on palbociclib or ribociclib conjugated with indocyanine green and self-assembled with human serum albumin; this probe specifically targeted the CDK4-cyclin D complex and enabled early, noninvasive visualization of response to CDK4/6 inhibitors, including discrimination between sensitive and resistant tumors.
Other studies examined resistance and combination strategies involving CDK4/6 inhibition. In breast cancer, PCK1 was identified as a factor associated with resistance to CDK4/6 inhibitors through interaction with Cyclin D3, which forms a complex with CDK4/6; everolimus and auranofin were reported to inhibit PCK1 and act synergistically with CDK4/6 inhibitors. In dedifferentiated liposarcoma, palbociclib was described as delaying disease progression by inducing tumor cell quiescence or senescence, with preclinical data suggesting that CDK4/6 inhibition may enhance intratumoral inflammation and potentially synergize with immune checkpoint inhibition. Additional clinical reports noted variability in ribociclib exposure in the setting of renal impairment and raised concern for atrial arrhythmias with CDK4/6 inhibitors, underscoring ongoing interest in both efficacy and safety as these agents are used more broadly.